During this period, the foundation for utilizing RAAS blockers to treat DN was established, with both angiotensin receptor blocker (ARBs) and angiotensin-converting-enzyme inhibitor (ACEIs) drugs effectively protecting against DN through RAAS-blocking activity, leading to improvements in proteinuria, renal blood flow, and blood pressure [34]. Here, ACE is linked to liver dysplastic nodule.